Filana Therapeutics (FLNA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Addressing past controversies and investor concerns

• Historical controversies led to significant stock declines and investor skepticism.

• Positive phase three results and biomarker data are expected to confirm drug efficacy and restore confidence.

• Leadership is focused on changing company perception and rebuilding trust.

Data generation and validation efforts

• Multiple independent experiments are underway to verify the drug's mechanism of action.

• Experiments are being conducted with commercial labs globally, with results to be reported post-phase three.

• Analysis of 2,000 plasma biomarker samples from phase two is being initiated, as previously committed to the FDA.

• The combination of phase three results, validated experiments, and biomarker data aims to provide robust evidence for regulators and investors.

Leadership and future outlook

• The new CEO is committed to transparency and data-driven communication.

• Emphasis on the dedication and professionalism of the team working toward Alzheimer's treatment.

• Leadership transition is seen as positive for guiding the company through the completion of phase three trials.